Panacea Biotec Limited shares demonstrated exceptional market performance, surging 6% to ₹407.60 on January 8, 2026, following the company's announcement of completing enrollment for its Phase III dengue vaccine trial. According to latest market data, this surge follows the previous day's gain of 4.85% to ₹384.05 on January 7, 2026. The company's market capitalization reached ₹2,352.33 crore with significant trading volume reflecting strong investor confidence. The stock's recent performance marks a notable recovery, with shares having traded between a 52-week high of ₹581.90 reached on May 15, 2025, and a low of ₹282.15 on February 28, 2025. According to recent trading data, Panacea Bio share price has gained 7.27% in the past five sessions and nearly 21% in a month, though the stock has declined by over 11% in the last year.
Panacea Biotec Limited has achieved a significant milestone by completing enrollment of study participants for the Phase III clinical trial of its tetravalent dengue vaccine candidate, DengiAll®. According to the company's regulatory disclosure filed on January 7, 2026, under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, the trial conducted in collaboration with the Indian Council of Medical Research has enrolled 10,335 participants across 19 locations in India. This milestone represents the culmination of a 17-year development journey that began in 2002, making it one of the longest vaccine development programs in Indian pharmaceutical history. The company has been actively working on the vaccine since 2008, when it became the second company globally to receive the novel dengue strain from the US National Institutes of Health. According to Panacea Biotec's Chief Scientific Officer Dr Syed Khalid Ali, DengiAll comes at a crucial time when half the world's population is at risk of dengue.
With enrollment now complete, Panacea Biotec will commence a comprehensive two-year monitoring period for each participant following administration of either the vaccine or a placebo. As reported by the company, this monitoring phase involves regular follow-ups with participants to evaluate the vaccine's efficacy and immunogenicity across all four dengue serotypes. According to Drug Controller General of India (DCGI) protocol, Panacea Biotec can conduct interim analysis once 124 confirmed dengue cases are recorded, potentially accelerating the approval timeline before the targeted market launch by 2027. The primary objectives include examining the vaccine's efficacy in preventing dengue infection and assessing its immunogenicity profile across all four dengue serotypes, though experts note that natural exposure to all serotypes may require extended observation periods. According to Dr Ali, every day of delay means denying people their lives as dengue cases and deaths continue to mount annually.
DengiAll® represents a breakthrough as India's first indigenous single-shot dengue vaccine and is expected to be the country's first indigenous single dose dengue vaccine. The vaccine utilizes live-attenuated, tetravalent technology using live, weakened strains of all four dengue virus serotypes DEN1, DEN2, DEN3 and DEN4 in a single dose, addressing the critical challenge of antibody-dependent enhancement that plagued previous vaccines. Initial Phase I and Phase II trials demonstrated 77-82% protection against all four dengue types, significantly outperforming existing vaccines. The development team overcame major technical challenges, including modifying the NIH strain to be stored at standard 2-8 degrees Celsius instead of the original -60 to -70 degrees requirement, making it viable for countries like India with diverse healthcare infrastructure. According to recent reports, this represents a notable achievement given the complexity of tackling dengue's four distinct strains in one vaccine formulation.
The development of DengiAll comes amid significant challenges in the global dengue vaccine landscape. According to industry reports, Sanofi had withdrawn its dengue vaccine Dengvaxia from the Philippines following safety concerns and later discontinued its manufacture in 2025 due to low demand. Studies had shown that Dengvaxia increased the risk of severe dengue in individuals who had not been previously infected, highlighting the complexity of dengue vaccine development. Other global efforts include Japanese drugmaker Takeda's dengue vaccine Qdenga introduced in 2022, while the Butantan Institute in Brazil has developed the Butantan DV vaccine, which is yet to enter commercial production. Health authorities continue to emphasize that preventing mosquito bites remains the primary line of defence against dengue, even as vaccine research progresses globally.
The latest market response reflects strong investor confidence in Panacea Biotec's vaccine development program, with the stock proving to be a wealth-creating machine for long-term investors, delivering multibagger returns of 8,670.33% since its listing. The vaccine's development addresses a critical global health need, with 14 million dengue cases reported worldwide in 2024 and climate change expanding mosquito habitats globally. According to company officials, over 10,000 people die annually from dengue, emphasizing the urgent need for effective prevention. The vaccine's single-shot formulation offers significant advantages in patient compliance and healthcare delivery efficiency compared to existing multi-dose regimens. If approved by 2027, DengiAll could transform dengue prevention not just in India but in other tropical regions where the disease poses a major public health threat, potentially establishing Panacea Biotec as a key player in the global vaccine market.
